Neogen Chemicals | Q3 FY25 Update
Neogen Chemicals reported a 22% YoY revenue growth, reaching ₹201 crore in Q3 FY25, fueled by expansion in its core business and contributions from BuLi Chem. Despite pricing headwinds, operational performance remained strong.
Neogen Ionics (NIL) began exporting lithium salts, adding to revenue. With new capacities coming online next year, NIL is set for significant growth.
EBITDA surged 71% to ₹34.6 crore, driven by improved plant utilization, operational efficiencies, and lower costs. Export sales helped reduce Neogen Ionics’ cost intensity.
Margins held firm at 17.2%, despite pricing pressure.
PAT skyrocketed 844% to ₹10 crore, benefiting from robust operations and a low base due to prior one-off costs. However, higher CAPEX in Neogen Ionics led to increased depreciation and interest expenses.
Lower bromine prices impacted revenue, which would have been ₹34 crore higher had prices remained stable. Similarly, the decline in lithium prices affected inorganic revenue, which would have been ₹13 crore higher in Q3 FY25 under stable pricing conditions.